Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | IDH1 | O75874 | 4/20 | 0.40 |
| ▸ | IDH2 | P48735 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127217 | 1.00 | CYP1A2 (0.45) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL19686807 | 0.86 | RAF1 (0.54) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| Hydrochloric Acid SCHEMBL23360593 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| Hydrochloric Acid SCHEMBL29862619 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL19686450 | 0.79 | SMN1; SMN2 (0.50) | MAPTRAF1KMT2ALRRK2EHMT2 | |
| SCHEMBL23275137 | 0.79 | RAF1 (0.52) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL31127374 | 0.79 | LRRK2 (0.42) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL21144012 | 0.79 | LRRK2 (0.42) | CYP1A2CYP2D6MAPTRAF1BRAF | |
| SCHEMBL19687073 | 0.79 | IDH1 (0.38) | CYP1A2MAPTRAF1KMT2AIDH1 | |
| SCHEMBL19687282 | 0.74 | KCNN3 (0.40) | MAPTKMT2AIDH1IDH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885CYP2D6 1366/4885MAPT 2009/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885CYP2D6 1366/4885MAPT 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.